Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab vs Bevacizumab in First-line Metastatic Colorectal Cancer
NCT07228832Phase 3Recruiting
- Sponsor
- Summit Therapeutics
- Start
- Nov 2025
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of ivonescimab in colorectal cancer (CRC), sponsored by Summit Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07228832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228832.